Trials / Recruiting
RecruitingNCT07035886
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
Post-Marketing Surveillance (Usage Results Study) of Fruzaqla Capsule (Fruquintinib) for the Approved Indications in South Korea
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | As this is an observational study, no intervention will be administered. |
Timeline
- Start date
- 2025-09-29
- Primary completion
- 2029-09-01
- Completion
- 2031-03-01
- First posted
- 2025-06-25
- Last updated
- 2026-02-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07035886. Inclusion in this directory is not an endorsement.